Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Randomized Study of Nandrolone Therapy for Anemias Due to Bone Marrow Failure

Randomized Study of Nandrolone Therapy for Anemias Due to Bone Marrow Failure Abstract A prospective, randomized, doubleblind study was designed to determine the effectiveness and toxicity of nandrolone phenpropionate in the treatment of anemias due to bone marrow failure. Twentyfour patients were initially entered; 21 now may be evaluated: seven with aplastic anemia, six with myelofibrosis, and eight with refractory anemia. Six patients improved, but only three were taking nandrolone, the other three placebo. Response did not correlate with type of anemia. No serious drug toxicity was noted. One patient with myelofibrosis improved dramatically with placebo therapy alone, no longer requiring frequent transfusions because of a hemoglobin level increase from 5.4 to 15.8 gm/100 ml. We conclude that no substantial improvement of anemia due to marrow failure can be ascribed to nandrolone as given, and that clinical trials in these conditions should be controlled to exclude spontaneous remissions as a cause of apparent improvement. (Arch Intern Med 137:65-69, 1977) References 1. Shahidi NT: Androgens and erythropoiesis . N Engl J Med 289:72-80, 1973.Crossref 2. Hindler ID, Goffinet JA, Ross S, et al: Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis . N Engl J Med 291:1046-1051, 1974.Crossref 3. O'Gorman Hughes DE: Aplastic anemia in childhood: A reappraisal . Med J Aust 2:361-366, 1973. 4. Heyn RM, Ertel IJ, Tubergen DG: Course of acquired aplastic anemia in children treated with supportive care . JAMA 208:1372-1378, 1969.Crossref 5. Lynch RE, Williams DM, Reading JC, et al: The prognosis in aplastic anemia . Blood 45:517-528, 1975. 6. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) and critical evaluation of its relationship with the myeloproliferative syndrome . Medicine 50:357-420, 1971.Crossref 7. Bovij J, Kuypers J: The haemopoietic effect of nandrolone phenylpropionate (Durabolin) . Acta Physiol Pharmacol Neerlandica 11:12-19, 1962. 8. Fried W, Gurney CW: The erythropoietic stimulating effects of androgens . Ann NY Acad Sci 149:356-365, 1968.Crossref 9. Naets JP, Wittek M: The mechanism of action of androgens on erythropoiesis . Ann NY Acad Sci 149:366-376, 1968.Crossref 10. Martins JK: Use of nandrolone phenpropionate in refractory anemias . Curr Ther Res 3:512-519, 1961. 11. Besa EC, Gorsheim D, Gardner FH: Androgens and human blood volume changes: Comparison in normal and various anemic states . Arch Intern Med 133:418-425, 1975.Crossref 12. Daiber A, Herve L, Con I, et al: Treatment of aplastic anemia with nandrolone decanoate . Blood 36:748-753, 1970. 13. Alexanian R: Erythropoietin and erythropoiesis in anemic man following androgens . Blood 33:564-572, 1969. 14. Duarte L, Lopez Sandoval R, Esquivel F, et al: Androstane therapy of aplastic anemia . Acta Haematol 47:140-145, 1972.Crossref 15. Sanchez-Medal L, Gomez-Leul A, Duarte L, et al: Anabolic androgenic steroids in the treatment of acquired aplastic anemia . Blood 34:283-300, 1969. 16. Gardner FH, Nathan DG: Androgens and erythropoiesis: III. Further evaluation of testosterone treatment of myelofibrosis . N Engl J Med 274:420-426, 1966.Crossref 17. Sachs P, Gale D, Bothwell TH, et al: Oxymetholone therapy in aplastic and other refractory anaemias . S Afr Med J 46:1607-1615, 1972. 18. Evens RP, Amerson AB: Androgens and erythropoiesis . J Clin Pharmacol 14:1-8, 1974.Crossref 19. Delamore IW, Geary CG: Aplastic anaemia, acute myeloblastic leukaemia and oxymetholone . Br Med J 2:743-745, 1971.Crossref 20. Pierre RV: Preleukemic states . Semin Hematol 11:73-92, 1974. 21. Johnson FL, Lerner KG, Siegal M, et al: Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma . Lancet 2:1273-1276, 1972.Crossref 22. Davis S, Rubin AD: Treatment and prognosis in aplastic anemia . Lancet 1:871-873, 1972.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Randomized Study of Nandrolone Therapy for Anemias Due to Bone Marrow Failure

Loading next page...
 
/lp/american-medical-association/randomized-study-of-nandrolone-therapy-for-anemias-due-to-bone-marrow-QLSU5n6T08
Publisher
American Medical Association
Copyright
Copyright © 1977 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1977.03630130041011
Publisher site
See Article on Publisher Site

Abstract

Abstract A prospective, randomized, doubleblind study was designed to determine the effectiveness and toxicity of nandrolone phenpropionate in the treatment of anemias due to bone marrow failure. Twentyfour patients were initially entered; 21 now may be evaluated: seven with aplastic anemia, six with myelofibrosis, and eight with refractory anemia. Six patients improved, but only three were taking nandrolone, the other three placebo. Response did not correlate with type of anemia. No serious drug toxicity was noted. One patient with myelofibrosis improved dramatically with placebo therapy alone, no longer requiring frequent transfusions because of a hemoglobin level increase from 5.4 to 15.8 gm/100 ml. We conclude that no substantial improvement of anemia due to marrow failure can be ascribed to nandrolone as given, and that clinical trials in these conditions should be controlled to exclude spontaneous remissions as a cause of apparent improvement. (Arch Intern Med 137:65-69, 1977) References 1. Shahidi NT: Androgens and erythropoiesis . N Engl J Med 289:72-80, 1973.Crossref 2. Hindler ID, Goffinet JA, Ross S, et al: Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis . N Engl J Med 291:1046-1051, 1974.Crossref 3. O'Gorman Hughes DE: Aplastic anemia in childhood: A reappraisal . Med J Aust 2:361-366, 1973. 4. Heyn RM, Ertel IJ, Tubergen DG: Course of acquired aplastic anemia in children treated with supportive care . JAMA 208:1372-1378, 1969.Crossref 5. Lynch RE, Williams DM, Reading JC, et al: The prognosis in aplastic anemia . Blood 45:517-528, 1975. 6. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) and critical evaluation of its relationship with the myeloproliferative syndrome . Medicine 50:357-420, 1971.Crossref 7. Bovij J, Kuypers J: The haemopoietic effect of nandrolone phenylpropionate (Durabolin) . Acta Physiol Pharmacol Neerlandica 11:12-19, 1962. 8. Fried W, Gurney CW: The erythropoietic stimulating effects of androgens . Ann NY Acad Sci 149:356-365, 1968.Crossref 9. Naets JP, Wittek M: The mechanism of action of androgens on erythropoiesis . Ann NY Acad Sci 149:366-376, 1968.Crossref 10. Martins JK: Use of nandrolone phenpropionate in refractory anemias . Curr Ther Res 3:512-519, 1961. 11. Besa EC, Gorsheim D, Gardner FH: Androgens and human blood volume changes: Comparison in normal and various anemic states . Arch Intern Med 133:418-425, 1975.Crossref 12. Daiber A, Herve L, Con I, et al: Treatment of aplastic anemia with nandrolone decanoate . Blood 36:748-753, 1970. 13. Alexanian R: Erythropoietin and erythropoiesis in anemic man following androgens . Blood 33:564-572, 1969. 14. Duarte L, Lopez Sandoval R, Esquivel F, et al: Androstane therapy of aplastic anemia . Acta Haematol 47:140-145, 1972.Crossref 15. Sanchez-Medal L, Gomez-Leul A, Duarte L, et al: Anabolic androgenic steroids in the treatment of acquired aplastic anemia . Blood 34:283-300, 1969. 16. Gardner FH, Nathan DG: Androgens and erythropoiesis: III. Further evaluation of testosterone treatment of myelofibrosis . N Engl J Med 274:420-426, 1966.Crossref 17. Sachs P, Gale D, Bothwell TH, et al: Oxymetholone therapy in aplastic and other refractory anaemias . S Afr Med J 46:1607-1615, 1972. 18. Evens RP, Amerson AB: Androgens and erythropoiesis . J Clin Pharmacol 14:1-8, 1974.Crossref 19. Delamore IW, Geary CG: Aplastic anaemia, acute myeloblastic leukaemia and oxymetholone . Br Med J 2:743-745, 1971.Crossref 20. Pierre RV: Preleukemic states . Semin Hematol 11:73-92, 1974. 21. Johnson FL, Lerner KG, Siegal M, et al: Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma . Lancet 2:1273-1276, 1972.Crossref 22. Davis S, Rubin AD: Treatment and prognosis in aplastic anemia . Lancet 1:871-873, 1972.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jan 1, 1977

References